NLV
OrganizationRelationship Network
| Connected Entity | Relationship Type |
Strength
(mentions)
|
Documents | Actions |
|---|---|---|---|---|
|
person
NLV-I
|
Management valuation |
5
|
1 |
| Date | Event Type | Description | Location | Actions |
|---|---|---|---|---|
| N/A | N/A | Closing of NLV-III fund. | View |
HOUSE_OVERSIGHT_024054.jpg
This document is page 43 of a confidential investment memorandum describing the 'Deal Sourcing & Investment Process' for a fund referred to as 'NLV'. It details the Fund Managers' strategy of tracking biopharma companies (specifically in Oncology, Infectious Disease, and CNS) and leveraging a high-level network of industry executives and scientists to identify investment opportunities. The page bears a House Oversight Bates stamp, indicating it was part of a congressional investigation.
HOUSE_OVERSIGHT_024013.jpg
This document appears to be page 2 of a confidential investment memorandum or prospectus for 'New Leaf' (NLV) funds, specifically discussing the transition of Jim Niedel to Venture Partner for the NLV-III fund. It highlights the 'Long Term Track Record' of the fund managers, noting they have invested over $1.6 billion since 1995 through NLV and Sprout Capital funds, consistently outperforming benchmarks like Cambridge Associates. The document bears a House Oversight Committee stamp, suggesting it was part of a congressional investigation.
HOUSE_OVERSIGHT_024012.jpg
This document is an Executive Summary for 'New Leaf Ventures III, L.P.' (NLV-III), a healthcare technology investment fund targeting $375 million in capital commitments. It details the history of the management company, New Leaf Venture Partners, outlining previous funds (NLV-I and NLV-II) and their affiliation with Sprout Group/Credit Suisse. The document lists the Managing Directors and outlines the fund's strategy to invest in 24-28 U.S.-based healthcare companies. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, indicating it was part of a congressional document production.
HOUSE_OVERSIGHT_024108.jpg
This document is Appendix 5 (Endnotes) of a confidential financial report dated as of March 31, 2014, obtained by the House Oversight Committee (Bates stamp HOUSE_OVERSIGHT_024108). It outlines the methodology for financial performance reporting for funds identified as NLV-I, NLV-II, and the Sprout Funds, distinguishing between 'gross' and 'net' performance and providing legal disclaimers regarding valuations and future results. The document defines the roles of generic 'Fund Managers' and the 'Sprout Group' in managing these investments.
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein entity